The Tokyo-based firm said it will use the funding to support prototyping and commercialization of its mass spectrometry and optical spectroscopy instruments.
The partners plan to validate the accuracy, effectiveness, and clinical implications of Group K's MultiNostic liver function test, which is pending FDA clearance.
Beyond its HostDx Sepsis test, the firm is working on a test to detect and differentiate bacterial from viral infections in patients presenting with fever.
The firm said its platform provides sample-to-answer results for two of the most frequently tested sexually transmitted infections, enabling rapid testing and treatment.
At the Henry Ford Health System in Southeast Michigan, bringing on the Roche Cobas Liat for flu testing led to a season of headaches before it started paying off.
Formerly known as Diassess, the Emeryville, California-based startup will use the funding to finance regulatory clearances and early commercialization.
In US influenza testing, providers see growth in placements within hospital emergency departments, physicians' offices, urgent care centers, and retail clinics.
